Tralokinumab

Generic name
Tralokinumab
Brand name
ATC Code
D11AH07

Tralokinumab

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information available (source: SmPC Adtralza)

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Atopic dermatitis
  • Subcutaneous
    • 12 years up to 18 years
      • Initial dose: 600 mg/dose, once only.
      • Maintenance dose: 300 mg/dose every 2 weeks.
        • In stable disease activity after 16 weeks, the dose may be decreased to 300 mg 1x every 4 weeks;
        • If no response has occurred after 16 treatment weeks, discontinuation of treatment should be considered.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

The safety profile in children 12 years and older was generally similar to that of adults. However conjunctivitis was less common in adolescents.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

OTHER DERMATOLOGICAL PREPARATIONS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Other dermatologicals
D11AX
Agents for dermatitis, excluding corticosteroids
D11AH08
D11AH05
D11AH02
D11AH01
OTHER DERMATOLOGICALS
D11AX

References

  1. LEO Pharma A/S, SmPC Adtralza (EU/1/21/1554/001) Rev 4; 29-11-2023 , www.ema.europa.eu
  2. LEO Pharma A/S, SmPC Adtralza (EU/1/21/1554/001) Rev 4; 29-11-2023, www.ema.europa.eu

Changes

Therapeutic Drug Monitoring


Overdose